Hood River Capital Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Hood River Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$42.5 - $63.11 $5.6 Million - $8.32 Million	-131,846 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$54.93 - $74.36 $261,741 - $354,325	4,765 Added 3.75%	131,846 $8.37 Million
Q1 2019 May 14, 2019	SELL	$39.87 - $69.36 $214,699 - $373,503	-5,385 Reduced 4.07%	127,081 $8.81 Million
Q4 2018 Feb 13, 2019	BUY	$38.89 - $77.3 $74,007 - $147,101	1,903 Added 1.46%	132,466 $5.76 Million
Q3 2018 Nov 14, 2018	SELL	$71.81 - $90.15 $58,596 - $73,562	-816 Reduced 0.62%	130,563 $9.97 Million
Q2 2018 Jul 30, 2018	BUY	$48.54 - $85.31 $249,932 - $439,261	5,149 Added 4.08%	131,379 $10.1 Million
Q1 2018 May 07, 2018	BUY	$44.33 - $58.52 $134,718 - $177,842	3,039 Added 2.47%	126,230 $6.44 Million
Q4 2017 Feb 07, 2018	BUY	$43.54 - $57.32 $387,375 - $509,976	8,897 Added 7.78%	123,191 $5.71 Million
Q3 2017 Nov 07, 2017	BUY	$49.79 - $66.32 $5.69 Million - $7.58 Million	114,294	114,294 $6.09 Million

326

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Hood River Capital Management LLC with notifications on news.